Olumacostat Glasaretil

Summary

Olumacostat Glasaretil (CHEMBL3989947) is a phase-3 clinical-stage small molecule; indicated across 1 condition including acne.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 1
• Chemistry: 481.6 Da · C26H43NO7

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3989947
Name	Olumacostat Glasaretil
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	89497391
Molecular formula	C26H43NO7
Molecular weight	481.6
InChIKey	FYJLDICZGDFWKP-UHFFFAOYSA-N

SMILES: CCCCCCCCCCCCCCOC1=CC=C(O1)C(=O)OCC(=O)N(C)CC(=O)OCC

IUPAC name: [2-[(2-ethoxy-2-oxoethyl)-methylamino]-2-oxoethyl] 5-tetradecoxyfuran-2-carboxylate

Also known as: DRM-01B, DRM01B, DRMO1B, Olumacostat glasaretil, Olumacostat glasaretilo, OLUMACOSTAT GLASARETIL

Patent coverage: 12 distinct patent families (33 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
acne	3	MONDO:0011438	EFO:0003894

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02431052	PHASE2	COMPLETED	A Dose-ranging Study of DRM01 in Subjects With Acne Vulgaris

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).